Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVR and ONLY ADVR -- Ignore unavailable to you. Want to Upgrade?

To: PAFOOFNICK who wrote (240)	3/22/2003 6:14:11 PM
From: Tadsamillionaire	Respond to of 278

ADVR Begins Planning for Late Stage Phase II AIDS Clinical Trial In Israel Tuesday March 18, 7:30 am ET Progress of Current AIDS Trial Leading Selikoff Center to Develop Protocols For Multi-Center, Blinded Controlled Trial YONKERS, N.Y., March 18 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR - News) today announced that, in consultation with the Selikoff Center, it has initiated activities necessary to expand the ongoing Israeli clinical trial of Product R for the treatment of AIDS patients on highly active antiretroviral therapy (HAART). The Company said it has directed the staff of the Selikoff Center in Israel, in collaboration with the principal investigator, to begin developing protocols for a multi-center, late stage Phase II clinical trial of Product R in AIDS patients who are in need of salvage therapy. biz.yahoo.com

To: PAFOOFNICK who wrote (240)	3/22/2003 6:15:57 PM
From: Tadsamillionaire	Read Replies (1) \| Respond to of 278

I am with you on this. Think it looks good long term.

To: PAFOOFNICK who wrote (240)	5/21/2005 8:21:25 PM
From: Tadsamillionaire	Respond to of 278

ADVR Awarded its Sixteenth Patent Wednesday May 18, 1:33 pm ET YONKERS, N.Y.--(BUSINESS WIRE)--May 18, 2005--Advanced Viral Research Corp. (OTC Bulletin Board: ADVR - News) announced today that the patent office in Mexico has granted the Company patent #225306 entitled "Preparation of a Therapeutic Composition" for AVR118. The patent describes the composition of AVR118 and methods of manufacturing it. "We continue to safeguard versatile applications for AVR118 and strengthen our intellectual property position," said Dr. Elma S. Hawkins, President and CEO of Advanced Viral Research Corp. "This patent increases ADVR's growing intellectual property position, which now includes 16 patents." Currently, ADVR is engaged in a Phase II, multi-center, randomized, double-blind United States study designed to evaluate the effect of a 4.0 ml dose of AVR118 administered to patients with systemic symptoms related to advanced cancers who are not candidates for, or who do not wish to receive, chemotherapy. ADVR's AVR118 represents a biopolymer that possesses novel immunomodulatory activity. This peptide-nucleic acid complex, which to date has demonstrated a very favorable safety profile, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papillomavirus, and to dampen aberrant autoimmune-type inflammatory responses, such as those which occur in patients with rheumatoid arthritis. The Phase I/II clinical trial of AVR118 in AIDS patients, which was conducted in Israel, concluded that AVR118 continues to demonstrate evidence of unique patient benefits, a favorable safety profile, and no apparent drug-related adverse events. Unique patient benefits included weight gain, mood improvement, decrease in fatigue, and increase in ability to perform everyday tasks. Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com. biz.yahoo.com